Drug ApprovalsRelapsed head and neck cancer gets first new FDA drug in 10 years
An injection of amivantamab shrank tumours in 42% of people whose head and neck cancer returned after immunotherapy and chemotherapy, earning FDA accelerated approval on 5 November.
5 November 2026